Vericel Corporation logo
Vericel Corporation VCEL
$ 31.41 -4.06%

Annual report 2025
added 02-26-2026

report update icon

Vericel Corporation Balance Sheet 2011-2026 | VCEL

Annual Balance Sheet Vericel Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-85.6 M -64.7 M 19 M -3.5 M -65.3 M -51 K 965 K -18.3 M -9.62 M -12.8 M -14.5 M -30.2 M -8.05 M -13.6 M -5.45 M

Long Term Debt

522 K 570 K 81.9 M 43.3 M 44 K - - - 16.9 M 9.35 M 71 K - - 6 K 40 K

Long Term Debt Current

14 M 9.26 M 6.19 M 4.3 M 2.95 M 4.39 M 5.46 M - - - - - 6 K 34 K 40 K

Total Non Current Liabilities

- - - - - - 22.4 M 1.67 M 18.9 M 11 M 71 K 109 K - 6 K 40 K

Total Current Liabilities

49.1 M 50.3 M 45.7 M 37.5 M 26.1 M 22.5 M 19.8 M 14.8 M 13.1 M 12.9 M 12.1 M 11.8 M 5.32 M 5.66 M 20.7 M

Total Liabilities

133 M 141 M 128 M 80.7 M 73.2 M 71.3 M 42.1 M 16.5 M 32 M 23.9 M 12.2 M 11.9 M 5.32 M 5.66 M 20.7 M

Retained Earnings

-376 M -393 M -403 M -400 M -383 M - -379 M -369 M -361 M -344 M -324 M -308 M -288 M -275 M -242 M

Total Assets

488 M 433 M 354 M 273 M 244 M 206 M 153 M 119 M 54.6 M 48.6 M 34.3 M 47.6 M 9.22 M 15.2 M 7.74 M

Cash and Cash Equivalents

100 M 74.5 M 69.1 M 51.1 M 68.3 M 33.6 M 26.9 M 18.3 M 26.9 M 23 M 14.6 M 30.3 M 8.06 M 13.6 M 5.53 M

Book Value

355 M 292 M 226 M 192 M 170 M 134 M 111 M 102 M 22.5 M 24.7 M 22.1 M 35.6 M 3.89 M 9.51 M -13 M

Total Shareholders Equity

355 M 292 M 226 M 192 M 170 M 134 M 111 M 102 M 22.5 M 24.7 M 22.1 M 35.6 M 3.89 M -32.1 M -13 M

All numbers in USD currency

Quarterly Balance Sheet Vericel Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

543 K 554 K 566 K 570 K 91.3 M 89.8 M 86.1 M 81.9 M 77.7 M 76.1 M 42.4 M 43.3 M - - 19 K 44 K 42 K 62 K 57 K 76 K 76 K 76 K 76 K 110 K 110 K 110 K 110 K - 13.2 M 14.4 M 15.6 M 16.9 M 7.4 M 16.9 M 16.9 M 9.32 M 42 K 9.32 M 9.32 M 71 K 81 K 71 K 71 K 109 K 115 K 109 K 109 K - - - 2 K 6 K 6 K 6 K 6 K 40 K 40 K 40 K 40 K

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - 1.67 M - - - 2.06 M - - - 1.69 M - - - - - - - 109 K - - - - - - - - - - - - - - -

Total Liabilities

131 M 129 M 129 M 141 M 133 M 134 M 123 M 128 M 114 M 112 M 71.1 M 80.7 M 70.2 M - 67.8 M 73.2 M 67.4 M 70.9 M 71.3 M 71.3 M 71.3 M 71.3 M 71.3 M 42.1 M 42.1 M 42.1 M 42.1 M 16.5 M 16.5 M 16.5 M 16.5 M 32 M 32 M 32 M 32 M 23.9 M 23.9 M 23.9 M 23.9 M 12.2 M 12.2 M 12.2 M 12.2 M 11.9 M 11.9 M 11.9 M 11.9 M 5.32 M 7.25 M 3.84 M 4.28 M 5.66 M 5.66 M 5.66 M 5.66 M 20.7 M 20.7 M 20.7 M 20.7 M

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - 534 K 503 K 426 K 420 K 506 K 515 K 420 K - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-400 M -405 M -404 M -393 M -413 M -412 M -407 M -403 M -416 M -413 M -407 M -400 M -406 M - -390 M -383 M -388 M -383 M -379 M -376 M -376 M -376 M -376 M -379 M -379 M -379 M -379 M -369 M -369 M -369 M -369 M -361 M -361 M -361 M -361 M -344 M -344 M -344 M -344 M -324 M -324 M -324 M -324 M - - - -294 M -288 M -285 M -287 M -282 M -275 M -275 M -275 M -275 M -242 M -242 M -242 M -242 M

Total Assets

453 M 436 M 425 M 433 M 390 M 377 M 357 M 354 M 318 M 311 M 265 M 273 M 248 M - 240 M 244 M 224 M 222 M 211 M 206 M 206 M 206 M 206 M 153 M 153 M 153 M 153 M 119 M 119 M 119 M 119 M 54.6 M 54.6 M 54.6 M 54.6 M 48.6 M 48.6 M 48.6 M 48.6 M 34.3 M 34.3 M 34.3 M 34.3 M 47.6 M 47.6 M 47.6 M 47.6 M 9.22 M 9.22 M 9.22 M 9.22 M 15.2 M 15.2 M 15.2 M 15.2 M 7.74 M 7.74 M 7.74 M 7.74 M

Cash and Cash Equivalents

100 M 80.5 M 73.5 M 74.5 M 53.7 M 50.3 M 62.9 M 69.1 M 60.5 M 43 M 61.8 M 51.1 M 65.2 M 56.1 M 55.7 M 68.3 M 54.6 M 51.8 M 58.2 M 33.6 M 33.6 M 33.6 M 33.6 M 26.9 M 26.9 M 26.9 M 26.9 M 18.3 M 18.3 M 18.3 M 18.3 M 26.9 M 26.9 M 26.9 M 26.9 M 23 M 23 M 23 M 23 M 14.6 M 14.6 M 14.6 M 14.6 M 30.3 M 30.3 M 30.3 M 30.3 M 8.06 M 10.8 M 4.49 M 9.23 M 13.6 M 13.6 M 13.6 M 13.6 M 5.53 M 5.53 M 5.53 M 5.53 M

Book Value

322 M 307 M 295 M 292 M 257 M 243 M 234 M 226 M 204 M 199 M 194 M 192 M 178 M - 172 M 170 M 157 M 151 M 140 M 134 M 134 M 134 M 134 M 111 M 111 M 111 M 111 M 102 M 102 M 102 M 102 M 22.5 M 22.5 M 22.5 M 22.5 M 24.7 M 24.7 M 24.7 M 24.7 M 22.1 M 22.1 M 22.1 M 22.1 M 35.6 M 35.6 M 35.6 M 35.6 M 3.89 M 1.96 M 5.37 M 4.94 M 9.51 M 9.51 M 9.51 M 9.51 M -13 M -13 M -13 M -13 M

Total Shareholders Equity

322 M 307 M 295 M 292 M 257 M 243 M 234 M 226 M 204 M 199 M 194 M 192 M 178 M 175 M 172 M 170 M 157 M 151 M 140 M 134 M 134 M 134 M 134 M 111 M 111 M 111 M 111 M 102 M 102 M 102 M 102 M 22.5 M 22.5 M 22.5 M 22.5 M 24.7 M 24.7 M 24.7 M 24.7 M 22.1 M 22.1 M 22.1 M 22.1 M 35.6 M 35.6 M 35.6 M 35.6 M 3.89 M 3.89 M 3.89 M 3.89 M -32.1 M -32.1 M -32.1 M -32.1 M -13 M -13 M -13 M -13 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Vericel Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.5 -1.39 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.0 2.25 % $ 315 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.34 -4.02 % $ 116 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.24 -2.97 % $ 704 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.8 -1.1 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.94 -3.29 % $ 3.43 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
$ 0.16 -5.45 % $ 3.15 M irlandaIrlanda
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA